FDA Approves Pylarify TruVu to Expand PSMA-PET Imaging Access for Prostate Cancer

from TheBrief.Health · host TheBrief.Health

Food and Drug Administration approved Pylarify TruVu, improving PSMA-PET availability and reliability, enabling better prostate cancer staging, earlier recurrence detection, and broader access to advanced diagnostic imaging.

Episode metadata supplied by the publisher feed · Published Apr 24, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

FDA Approves Pylarify TruVu to Expand PSMA-PET Imaging Access for Prostate Cancer

0:00 1:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of TheBrief.Health?

This episode is 1 minute long.

When was this TheBrief.Health episode published?

This episode was published on April 24, 2026.

Can I download this TheBrief.Health episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!